Sugi Predict

Sugi Predict / Compounds / SCHEMBL525302

SCHEMBL525302

SCHEMBL525302

Fc1ccc(N=Cc2ccc(OCc3ccccc3)cc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.77
▸ ALDH1A1 P00352 3/20 0.77
▸ MEN1 O00255 3/20 0.77
▸ KMT2A Q03164 3/20 0.77
▸ L3MBTL1 Q9Y468 2/20 0.77
▸ GAA P10253 1/20 0.77
▸ MAPT P10636 1/20 0.77
▸ THRB P10828 1/20 0.77
▸ PKM P14618 1/20 0.77
▸ CASP3 P42574 1/20 0.77
▸ RECQL P46063 1/20 0.77
▸ BLM P54132 1/20 0.77
▸ PLEC Q15149 1/20 0.77
▸ SENP8 Q96LD8 1/20 0.77
▸ SENP7 Q9BQF6 1/20 0.77
▸ SENP6 Q9GZR1 1/20 0.77
▸ CA12 O43570 1/20 0.67
▸ CA9 Q16790 1/20 0.67
▸ MAOB P27338 13/20 0.65
▸ SMN1; SMN2 Q16637 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12275030 1.00 KDM4E (0.77) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL1032816 1.00 KDM4E (0.77) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL13980482 0.90 KDM4E (0.83) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL8806871 0.86 KDM4E (0.77) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL8806870 0.86 KDM4E (0.77) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL23785508 0.85 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL7828469 0.82 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL7828471 0.82 KDM4E (0.76) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL3824529 0.81 MAOB (0.67) KDM4EALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4299698 0.81 MAOB (0.67) KDM4EALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119033944-A Medicine for hypercholesteremia and preparation method thereof 黔南民族医学高等专科学校 2024-11-29 — — CN claimed
CN-107356682-B HPLC method for detecting 4-benzyloxy benzylidene aniline in 4-benzyloxy benzylidene-4-fluoroaniline 先声药业有限公司 2021-06-29 — — CN claimed
CN-107356682-A A kind of HPLC methods of 4- benzyloxy benzylidene anilines in detection 4- benzyloxy benzylidene -4- fluoroanilines 南京先声东元制药有限公司 2017-11-17 — — CN claimed
CN-107176920-A A kind of new technique for synthesizing of ezetimibe 上海恒晟药业有限公司 2017-09-19 — — CN claimed
US-20090227786-A1 PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF EZETIMIBE MEDICHEM S.A. (ES) 2009-09-10 — — US claimed
EP-1971573-A2 PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF EZETIMIBE Medichem S.A. (ES) 2008-09-24 — — EP claimed
WO-2007119106-A2 PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF EZETIMIBE MEDICHEM, S.A. (US) 2007-10-25 — — WO claimed
WO-2025238757-A1 SECONDARY BATTERY ＮＴＴ株式会社 2025-11-20 — — WO disclosed
WO-2025238768-A1 LITHIUM SECONDARY BATTERY ＮＴＴ株式会社 2025-11-20 — — WO disclosed
CN-119033944-A Medicine for hypercholesteremia and preparation method thereof 黔南民族医学高等专科学校 2024-11-29 — — CN disclosed
CN-107488190-B Ezetimibe intermediate and preparation method thereof 山东新时代药业有限公司 2021-07-02 — — CN disclosed
CN-107356682-B HPLC method for detecting 4-benzyloxy benzylidene aniline in 4-benzyloxy benzylidene-4-fluoroaniline 先声药业有限公司 2021-06-29 — — CN disclosed
CN-107356682-B HPLC method for detecting 4-benzyloxy benzylidene aniline in 4-benzyloxy benzylidene-4-fluoroaniline 先声药业有限公司 2021-06-29 — — CN disclosed
US-5688990-A FORMING CHEMICAL INTERMEDIATES FOR AZETIDINONE COMPOUNDS THAT INHIBIT CHOLESTEROL BIOSYNTHESIS FOR PREVENTION OF ATHEROSCLEROSIS SHANKAR BANDARPALLE B (US) 1997-11-18 — — US disclosed
US-5631365-A TREATING LACTONE WITH BASE; REACTING WITH AROMATIC IMINE; LACTAMIZATION SCHERING CORPORATION (US) 1997-05-20 — — US disclosed
US-5627176-A MIXED WITH CHOLESTEROL BIOSYNTHESIS INHIBITOR; PREVENTING ATHEROSCLEROSIS SCHERING CORPORATION (US) 1997-05-06 — — US disclosed
EP-0751934-A1 SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS SCHERING CORPORATION (US) 1997-01-08 — — EP disclosed
EP-0720599-A1 HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS SCHERING CORPORATION (US) 1996-07-10 — — EP disclosed
WO-1995026334-A1 SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS SCHERING CORPORATION (US) 1995-10-05 — — WO disclosed
WO-1995008532-A1 HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS SCHERING CORPORATION (US) 1995-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227786-A1 PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF EZETIMIBE PCSK9, HMGCR, NPC1L1 KDM4E 336/4885ALDH1A1 257/4885MEN1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.